Search TRLV
Trulieve Cannabis Corp.
NYSE · CIK 1754195
Last close10.72
Daily change-0.15 (-1.38%)
10 Years gain+2.03%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
TRLV · STANDARD
SIC 2833 · Medicinal Chemicals & Botanical Products · Fiscal year end 1231
Fundamental
30.2Momentum
0.0Acceleration
0.0Confidence
91.0Annual Revenue7
Quarterly Revenue20
Annual CFO7
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth0.3 / 25
Quality6.9 / 25
Capital Efficiency1.7 / 20
Balance Sheet14.4 / 15
Shareholder Economics6.9 / 10
Forward Indicators0.0 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Warnings
Operating margin compression · MEDIUMOperating margin compressed by 31.8708 percentage points.
ROIC declining · MEDIUMROIC declined by 25.9217 percentage points.
Key Metrics
Revenue Growth TTM-2.97%OK
Revenue CAGR 3Y-1.02%OK
Gross Margin59.68%OK
Operating Margin-20.9%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-20.04%OK
Incremental Operating Margin 3Y-587.14%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y0.83%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $1.18B | $711.17M | $143.50M | $272.82M | $228.63M | 60.21% | 12.15% | 19.36% | 7.98% | 191.32M |
| 2025 FY Dec 31, 2024 | $1.19B | $715.75M | $97.78M | $271.48M | $148.88M | 60.32% | 8.24% | 12.55% | 4.41% | 189.99M |
| 2025 FY Dec 31, 2023 | $1.13B | $588.63M | -$221.61M | $201.84M | $161.60M | 52.13% | -19.63% | 14.31% | -9.14% | 188.97M |
| 2024 FY Dec 31, 2022 | $1.22B | $689.13M | $50.17M | $23.10M | -$141.65M | 56.57% | 4.12% | -11.63% | 1.71% | 188M |
| 2023 FY Dec 31, 2021 | $931.93M | $566.57M | $204.05M | $12.90M | -$263.00M | 60.8% | 21.9% | -28.22% | 9.88% | 146.76M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $1.15B | sum latest 4 fiscal quarters Revenue | OK | 0001754195-26-000069, 0001754195-25-000067 |
| Revenue Growth TTM | -2.97% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001754195-26-000069, 0001754195-25-000067 |
| Revenue CAGR 3Y | -1.02% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001754195-26-000019 |
| Revenue CAGR 5Y | 17.76% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001754195-26-000019 |
| Gross Profit CAGR 3Y | 1.05% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001754195-26-000019 |
| Operating Income Growth | -284.85% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0001754195-26-000069, 0001754195-25-000067 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 59.68% | Gross Profit / Revenue | OK | 0001754195-26-000069, 0001754195-25-000067 |
| Operating Margin | -20.9% | Operating Income / Revenue | OK | 0001754195-26-000069, 0001754195-25-000067 |
| ROIC | -20.04% | NOPAT / Average Invested Capital | OK | 0001754195-26-000069, 0001754195-25-000067 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001754195-26-000069 |
| Current Ratio | 5.94x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 1.66x | (Cash + Short-term Investments) / Total Debt | OK | 0001754195-26-000069 |
| Revenue per Diluted Share | $5.96 | Revenue / Diluted Shares | OK | 0001754195-26-000069, 0001754195-25-000067 |